非小细胞肺癌新辅助治疗的进展

Abstract
Figure/Table
References (31)
Related Citation (15)

Download: PDF (555 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Lung cancer is a malignant tumor with the highest morbidity and mortality in the world, and non-small cell lung cancer (NSCLC) is the most common type. At present, chest CT is widely used in clinical and physical examinations, and more and more early lung cancers are found, but there are still more patients with advanced lung cancer. For patients with locally advanced NSCLC, postoperative adjuvant treatments, including radiotherapy and chemotherapy, immunotherapy, and targeted therapy have been shown to significantly improve the prognosis of patients. The latest research shows that the preoperative neoadjuvant treatment has good tolerance and treatment compliance, does not increase the risk of complications and death of surgery, and provides more opportunities for surgical treatment and reduces disease recurrence, while improves the overall cure rate. At the same time, the combined application trials of these neoadjuvant treatments are also underway, and the results are expected. This article discusses the effects of different neoadjuvant treatments for NSCLC, reviews its latest developments, and provides references for clinical research.

Key words： Non-small cell lung cancer Neoadjuvant therapy Radiotherapy Chemotherapy Immunotherapy Targeted therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHI Hubo1 XU Yihui2

Cite this article:

SHI Hubo1 XU Yihui2. Progress in neoadjuvant therapy of non-small cell lung cancer[J]. 中国医药导报, 2021, 18(3): 43-47.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I3/43

[1] Mountain CF，McMurtrey MJ，Frazier OH. Current results of surgical treatment for lung cancer [J]. Cancer Bull，1980，32（1）：105-108.
[2] Group NM-AC. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer：a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials [J]. J Clin Oncol，2008，26（28）：4617-4625.
[3] Kris MG，Johnson BE，Berry LD，et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs [J]. JAMA，2014，3119（19）：1998-2006.
[4] Reck M，Rodriguez-Abreu D，Robinson AG，et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J]. N Engl J Med，2016，375（19）：1823-1833.
[5] Group NM-aC，Arriagada R，Auperin A，et al. Adjuvant chemotherapy，with or without postoperative radiotherapy，in operable non-small-cell lung cancer： two meta-analyses of individual patient data [J]. Lancet，2010，375：1267-1277.
[6] Group NM-AC. Preoperative chemotherapy for non-small-cell lung cancer：a systematic review and meta-analysis of individual participant data [J]. Lancet，2014，383（9928）：1561-1571.
[7] Rosell R，Felip E，Maestre J，et al. The role of chemotherapy in early non-small-cell lung cancer management [J]. Lung Cancer，2001，34（Suppl 3）：63-74.
[8] PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer：systematic review and meta-analysis of individual patient data from nine randomised controlled trials [J]. Lancet，1998，352（9124）：257-263.
[9] Blumenthal GM，Bunn PA，Chaft JE，et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer [J]. J Thorac Oncol，2018，13（12）：1818-1831.
[10] Bromley LL，Szur L. Combined radiotherapy and resection for carcinoma of the bronchus; experiences with 66 patients [J]. Lancet，1955，269（6897）：937-941.
[11] Shields TW，Higgins GA Jr，Lawton R，et al. Preoperative X-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma [J]. J Thorac Cardiovasc Surg，1970， 59（1）：49-61.
[12] Jett JR. Superior sulcus tumors and Pancoast’s syndrome [J]. Lung Cancer，2003，42（Suppl 2）：S17-S21.
[13] Postmus PE，Kerr KM，Oudkerk M，et al. Early and locally advanced non-small-cell lung cancer （NSCLC）：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up [J]. Ann Oncol，2017，28（4）：iv1-iv21.
[14] Thomas M，Rube C，Hoffknecht P，et al. Effect of preoperative chemoradiation in addition to preoperative chem-otherapy：a randomised trial in stage Ⅲ non-smallcell lung cancer [J]. Lancet Oncol，2008，9（7）：636-648.
[15] Martin J，Ginsberg RJ，Venkatraman ES，et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer [J]. J Clin Oncol，2002，20（8）：1989-1995.
[16] Pless M，Stupp R，Ris HB，et al. Induction chemoradiation in stage ⅢA/N2 non-small-cell lung cancer：a phase 3 randomised trial [J]. Lancet，2015，386：1049-1056.
[17] Antonia SJ，Villegas A，Daniel D，et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage Ⅲ NSCLC [J]. N Engl J Med，2018，379（24）：2342-2350.
[18] Gandhi L，Rodriguez-Abreu D，Gadgeel S，et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J]. N Engl J Med，2018，378（22）：2078-2092.
[19] Paz-Ares L，Luft A，Vicente D，et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J]. N Engl J Med，2018，379（21）：2040-2051.
[20] Socinski MA，Jotte RM，Cappuzzo F，et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J]. N Engl J Med，2018，378（24）：2288-2301.
[21] Forde PM，Chaft JE，Pardoll DM. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer [J]. N Engl J Med，2018，378（21）：1976-1986.
[22] Cottrell TR，Thompson ED，Forde PM，et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma：a proposal for quantitative immune-related pathologic response criteria （irPRC） [J]. Ann Oncol，2018，29（8）：1853-1860.
[23] Cascone T，William WN，Weissferdt A，et al. Neoadjuvant nivolumab （N） or nivolumab plus ipilimumab （NI） for resectable non-small cell lung cancer （NSCLC） [J]. Ann Oncol，2018，29：Ab LBA49.
[24] Rusch VW，Chaft JE，Johnson B，et al. Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer （NSCLC）：Updated Results from a Multicenter Study （LCMC3） [J]. J Thorac Oncol，2018，13（10）：8532.
[25] Shu CA，Grigg C，Chiuzan C，et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer （NSCLC） [J]. J Clin Oncol，2018，36（Suppl 15）：8532-8532.
[26] Nadal E，Insa A，Campelo RG，et al. Phase Ⅱ Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages ⅢA Non-Small Cell Lung Cancer- Nadim Study-SLCG [J]. J Thorac Oncol，2018，13（10）：S320.
[27] Corey JL，Shirish MG，Hossein B，et al. OA04.05 KEYN- OTE-021：TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamous NSCLC [J]. J Thorac Oncol，2019，14（Suppl 10）：S216.
[28] Marina CG，Delvys RA，Shrish MG，et al. OA04.06 evaluation of TMB in KEYNOTE-189：Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC [J]. J Thorac Oncol，2019，14（Suppl 10）：S216.
[29] Lee JH，Saw RP，Thompson JF，et al. Preoperative ctDNA predicts survival in high-risk stage Ⅲ cutameous melanoma patients [J]. Ann Oncol，2019，30（5）：815-822.
[30] Kelly K，Altorki NK，Eberhardt WE，et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage ⅠB-ⅢA Non-Small-Cell Lung Cancer （RADIANT）：A Randomized，Double-Blind，Phase Ⅲ Trial [J]. J Clin Oncol，2015，33（34）：4007-4014.
[31] Zhong WZ，Wang Q，Mao WM，et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA （N1-N2） EGFR-mutant NSCLC （ADJUVANT/CTONG1104）： a randomised，open-label，phase 3 study [J]. Lancet Oncol，2018，19（1）：139-148.